Search

Risperidone (generic) Risperdal (brand) [ABSTRACT FROM AUTHOR]

Atypical antipsychotic medications in children with autism spectrum disorder (ASD) are indicated for related irritability and agitation. These medications are associated with weight gain and metabolic complications, so researchers wanted to evaluate the efficacy of metformin. [ABSTRACT FROM AUTHOR]

While risperidone has been shown to be effective for short‐term (8‐week and 6‐month) management of severe irritability and aggression in children and adolescents with autism, less is known about long‐term effects. Researchers looked at tolerability, safety, and therapeutic benefits of long‐term use of the medication and found that the risks — weight gain, enuresis, and increased appetite — were balanced by the benefits. [ABSTRACT FROM AUTHOR]

There are no known pharmacotherapies for autism spectrum disorder (ASD); however, clinicians commonly prescribe psychotropic medication for behaviors and symptoms associated with ASD. Researchers conducted a review of studies looking at which medications work for what behaviors and symptoms. [ABSTRACT FROM AUTHOR]

The article focuses on a follow-up study for a trial which compared the use of risperidone to medications in combination with parent training for behavioral management in children with autism spectrum disorders and severe irritability. The study shows that the advantage of combination treatment over medication alone dissipated by more than half one year after completion of the original study. The researchers found no significant differences in medication use between the two treatment groups.

Whole exome sequencing (WES) is done to find a genetic cause of signs and symptoms; it looks at more genes than most genetic tests, and may find a cause that previous testing did not. [ABSTRACT FROM AUTHOR]

Children with autism spectrum disorder (ASD) have impairments in social communications and restricted repetitive behaviors as core symptoms. They also have a high incidence of irritability, aggression, and hyperactivity. While there is no medication approved for core symptoms of ASD, risperidone and aripiprazole have been approved for irritability and aggression associated with ASD. [ABSTRACT FROM AUTHOR]

The article offers information related to atypical antipsychotics Risperidone. Topics discussed include the function of the medicine as treatment for schizophrenia in adolescents and adults, risks and side effects forutilization of the drug including neuroleptic malignant syndrome (NMS), tardive dyskinesia (TD), and hyperglycemia, and doses for intake of the drug.

The article focuses on the study on the association of long-term risperidone to sexual effects in young males with autism spectrum disorders or disruptive behavior disorders. The study was participated by a total of 98 young males who were recruited from an outpatient adolescent clinic in the Netherlands. The result of the study shows that problems reported include diminished ability to have an orgasm and diminished ejaculation.

The article reports on a study that found high rates of hyperprolactinemia among risperidone-treated youth. Results indicated a possibility of gynecomastia and sexual dysfunction in relation to risperidone treatment. Researchers have further concluded that hyperprolactinemia is a common side effect among individuals undergoing long term treatment with risperidone.

The article offers information about the atypical antipsychotics risperidone. It notes that the drug has Food and Drug Administration (FDA)-approved indications for the treatment of schizophrenia and short-term treatment of acute mania or mixed episodes associated with bipolar disorder. Also offered are the potential risks and side effects of risperidone therapy as well as there interactions with drugs or foods.

Autism has no pharmaceutical treatment; however, risperidone is used in managing irritability associated with the disorder. Building on evidence that autism may be related to inflammation, researchers looked at the minocycline, a tetracycline antibiotic, in combination with risperidone in treating children with autism. [ABSTRACT FROM AUTHOR]

The article reports that a relatively large-scale placebo controlled study published in the November 2004 issue of "Pediatrics," investigated the efficacy and safety of the atypical antipsychotic risperidone for the treatment of disruptive behaviors in children with autism and other pervasive developmental disorders (PDD). Results were encouraging on all other subscales of the ABC, with the most significant difference observed for the hyperactivity/noncompliance subscale, for which risperidone-treated subjects experienced a decrease of 14.9 in mean score, while placebotreated subjects experienced a decrease of 7.4.

Reports on research works on child and adolescent psychopharmacology. Target dose of risperidone; Effectiveness of citalopram for adolescent depression; Additional health benefits of ziprasidone; Study of the use of amantadine for autistic symptoms.

The article presents a retrospective study on the systematic review of evidence on the medication treatment for 13 to 30-years-old with autism spectrum disorders (ASDs). The study involves searched Medline, ERIC, and Psyc-INFO databases from 1980 to December 2011. The results highlight the lack of evidence on all care areas for young adults and adolescents with ASD.

The article reports on the findings of a study on the efficacy of risperidone in improving maladaptive behaviors in autism.

The article reports on the findings of a study which investigates the efficacy of a cyclooxygenase-2 inhibitor added to risperidone in the treatment of autism.

The article presents a case study of a 15-year-old boy who was diagnosed with autistic disorder, mental retardation, and Tourette Syndrome and had undergone oculogyric crises caused by low-dosed risperidone.